Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
What this study shows
Defined two distinct TOR complexes, only one rapamycin-sensitive, founding the TORC1/TORC2 paradigm.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Yeast S. cerevisiae) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Yeast S. cerevisiae |
| Journal | Molecular cell |
| Year | 2002 |
| Peer reviewed | Yes |
| Record last updated | 2026-08-22 |
| Source | DOI 10.1016/s1097-2765(02)00636-6 · PMID 12408816 |
Extracted findings
| Intervention | Genetic/biochemical (TOR1/TOR2 complexes) |
| Target | TORC1 / TORC2 |
| Model | Yeast (S. cerevisiae) |
| Effect | Defines two TOR complexes: TORC1 (rapamycin-sensitive, growth) and TORC2 (rapamycin-insensitive, actin) |
In the Atlas
Related topics
More studies on this topic
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive (2004)
- Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton (2004)
Learn the biology
Want to understand the biology behind this study? → mTORC1 vs mTORC2